Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic VEGF dynamics with ranibizumab versus aflibercept in diabetic macular edema
2014-001639-35Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2014
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial in diabetic macular edema (DME) comparing Ranibizumab monthly from baseline with Aflibercept then ranibizumab (2 arms). Primary endpoint: Systemic VEGF-A protein AUC from baseline to week 12. Started Jul 2014; status: completed.
02
Drugs
ranibizumabaflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on 2014-001639-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001639-35.